Deborah Stahlnecker, DO
Pulmonary Disease · Fountain Hill, PANPI 1194933515
Payments from drug & device makers
Across 58 payments — averaging $321.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$10K
- Intuitive Surgical$5K
- Olympus America Inc.$2K
- Johnson & Johnson$645
- Steris Corporation$89
- Genentech USA, Inc.$40
What the payments were for
- Consulting fees$9,02548%
- Speaking & faculty fees$1,5008%
- Travel & lodging$2,21112%
- Food & beverage$1,86410%
- Education$4,04022%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 34 | $10,458 |
| Intuitive Surgical | 9 | $4,950 |
| Olympus America Inc. | 6 | $2,458 |
| Johnson & Johnson | 7 | $645 |
| Steris Corporation | 1 | $89 |
| Genentech USA, Inc. | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$9,746
- Da Vinci Surgical System$4,784
- EVIS EXERA II ULTRASONIC BRONCHOFIBERVIDEOSCOPE$1,500
- EVES EUS ULTRASOUND BRONCHOFIBERVIDEOSCOPE$900
- Single Use Aspiration Needle NA-U401SX$900
- CHARTIS CATHETER$565
- ZEPHYR DELIVERY CATHETER$565
- PULMONX CHARTIS TABLET CONSOLE$565
- Monarch Platform$416
How this compares
$18,640 in reported general payments places this provider in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 237 | $199,400 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 12 | $148,139 |
| Spiriva RespimatTiotropium Bromide | 63 | $49,741 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $38,314 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $34,372 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $29,156 |
| EliquisApixaban | 36 | $24,217 |
| Incruse ElliptaUmeclidinium Bromide | 47 | $19,339 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 87 | $14,848 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $13,879 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 54 | $10,039 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $7,858 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $7,221 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 238 | $7,217 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,838 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Fountain Hill
- Douglas CorwinFountain Hill$192K
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.